



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

5 May 2015
EMA/COMP/125607/2015
Committee for Orphan Medicinal Products

Public summary of opinion on orphan designation

[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for the treatment of tenosynovial giant cell tumour, localised and diffuse type

On 19 March 2015, orphan designation (EU/3/15/1457) was granted by the European Commission to Daiichi Sankyo Development Ltd, United Kingdom, for [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for the treatment of tenosynovial giant cell tumour, localised and diffuse type.

What is tenosynovial giant cell tumour, localised and diffuse type?

Tenosynovial giant cell tumour is a condition where the tissue surrounding the joints and tendons, called the synovial lining or synovium, expands abnormally forming outgrowths of the joint. It is known as 'diffuse' if the entire synovium is affected, or 'localised' if only a section of the synovium is affected. It usually affects the hand joint of young adults and is characterised by pain, swelling and stiffness of the joint.

Tenosynovial giant cell tumour is a long-term debilitating disease because it causes the destruction of joints.

What is the estimated number of patients affected by the condition?

At the time of designation, tenosynovial giant cell tumour, localised and diffuse type, affected not more than 2 in 10,000 people in the European Union (EU). This was equivalent to a total of not more than 153,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).



What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of tenosynovial giant cell tumour and treatment consisted of surgery.

How is this medicine expected to work?

The medicine is expected to work by blocking a receptor called CSF1R to which a protein called macrophage colony-stimulating factor (M-CSF) attaches. M-CSF is produced in large amounts by tenosynovial giant cell tumours, where it stimulates immune cells called macrophages to accumulate in the joints and cause the outgrowths. By attaching and blocking CSF1R, the medicine is expected to block the activity of M-CSF, preventing tumour growth and helping to delay the onset of the symptoms of the disease.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, a clinical trial with the medicine in patients with tenosynovial giant cell tumour, localised and diffuse type was ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for tenosynovial giant cell tumour, localised and diffuse type. Orphan designation of the medicine had been granted in United States for treatment of pigmented villonodular synovitis/giant cell tumour of the tendon sheath.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 12 February 2015 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information

Sponsor's contact details:

Daiichi Sankyo Development Ltd
Chiltern Place
Chalfont Park
Gerrards Cross
Buckinghamshire SL9 0BG
United Kingdom
Tel. +44 (0)1753 893 600
Fax +44 (0)1753 899 107
E-mail: info@dsd-eu.com

For contact details of patients' organisations whose activities are targeted at rare diseases see:

- [Orphanet](#), a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;
- [European Organisation for Rare Diseases \(EURORDIS\)](#), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Translations of the active ingredient and indication in all official EU languages¹, Norwegian and Icelandic

Language	Active ingredient	Indication
English	[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride	Treatment of tenosynovial giant cell tumour, localised and diffuse type
Bulgarian	[5-(5-хлоро-1Н-пироло[2,3-б]пиридин-3-илметил)-пиридин-2-ил]-(6-трифлуорометил-пиридин-3-илметил)-амин хидрохлорид	Лечение на теносиновиален гигантоклетъчен тумор, локализиран и дифузен тип
Croatian	[5-(5-kloro-1H-pirololo[2,3-b]piridin-3-ilmetil)-piridin-2-il]-(6-trifluorometil-piridin-3-ilmetil)-aminklorid	Liječenje gigantomcelularnog tenosinovijalnog tumora, lokaliziranog i difuznog tipa
Czech	[5-(5-chlor-1H-pyrrol[2,3-b]pyridin-3-yl-methyl)-pyridin-2-yl]-(6-trifluormethyl-pyridin-3-yl-methyl)-amin hydrochlorid	Léčba tenosynoviálního obrovskobuněčného tumoru, lokalizovaného a difuzního typu
Danish	[5-(5-chlor-1H-pyrrol[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-aminhydrochlorid	Behandling af tenosynovial kæmpecelletumor, lokaliseret og diffus type
Dutch	[5-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-ylmethyl)-pyridine-2-yl]-(6-trifluoromethyl-pyridine-3-ylmethyl)-amine hydrochloride	Behandeling van tenosynoviale reusceltumoren, van het gelokaliseerde en diffuse type
Estonian	[5-(5-kloro-1H-pürrool[2,3-b]püridiin-3-üülmētüül)-püridiin-2-üül]-(6-trifluorometüül-püridiin-3-üülmētüül)-amiin hüdrokloriid	Lokaalset ja difuusset tüüpi tenosünoviaalse hüdrakulise kasvaja ravi
Finnish	[5-(5-kloro-1H-pyrrolo[2,3-b]pyridiini-3-yylimetyyli)-pyridiini-2-yyli]-(6-trifluorometyyli-pyridiini-3-yylimetyyli)-aminihydrokloridi	Jännetupen jättisolukasvaimen hoito, paikallinen ja levinnyt tyyppi
French	Chlorhydrate de [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylméthyl)-pyridin-2-yl]-(6-trifluorométhyl-pyridin-3-ylméthyl)-amine	Traitement des tumeurs téno-synoviales à cellules géantes, de type localisées et diffuses
German	[5-(5-Chlor-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluormethyl-pyridin-3-ylmethyl)-aminhydrochlorid	Behandlung des tenosynovialen Riesenzelltumors vom lokalisierten und diffusen Typ
Greek	Υδροχλωρική [5-(5-χλωρο-1Η-πυρρολο[2,3-β]πυριδινό-3-υλμεθυλ)-πυριδινό-2-υλ]-(6-τριφθορομεθυλ-πυριδινό-3-υλμεθυλ)-αμίνη	Θεραπεία του τενοντο-αρθρικού γιγαντοκυτταρικού όγκου, εντοπισμένου και διάχυτου τύπου

¹ At the time of designation

Language	Active ingredient	Indication
Hungarian	[5-(5-klór-1H-pirrolo[2,3-b]piridin-3-ilmetil)-piridin-2-il]-(6-trifluorometil-piridin-3-ilmetil)-amin hidroklorid	Lokalizált és diffúz típusú tenosynovialis óriássejtes tumor kezelésére
Italian	[5-(5-cloro-1H-pirrolo[2,3-b]piridin-3-ilmetil)-piridin-2-il]-(6-trifluorometil-piridin-3-ilmetil)-ammina idrocloruro	Trattamento di sinovite pigmentata villonodulare e tumore tenosinoviale a cellule giganti di tipo localizzato e diffuso
Latvian	[5-(5-hloro-1H-pirollo[2,3-b]piridīn-3-ilmetil)-piridīn-2-il]-(6-trifluorometil-piridīn-3-ilmetil)-amīna hidrohlorīds	Norobežota vai difūza tipa tenosinoviālo gigantisko šūnu audzēja ārstēšana
Lithuanian	[5-(5-chloro-1H-pirollo[2,3-b]piridin-3-ilmetil)-piridin-2-il]-(6-trifluorometil-piridin-3-ilmetil)-amino hidrochloridas	Tenosinovialinių stambiųjų ląstelių lokalaus ir išplitusio tipo naviko gydymas
Maltese	[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride	Kura ta' tumor tenosinovjali ta' ċelluli ġganti, tat-tip lokalizzat u mxxerred
Polish	Chlorowodorek [5-(5-chloro-1H-pirollo[2,3-b]pyridyno-3-ylometylo)-pyridyno-2-ylo]-(6-trifluorometylo-pyridyno-3-ylometylo)-aminy	Leczenie guza olbrzymiokomórkowego pochewki ścięgnistej, miejscowego i rozsianego typu
Portuguese	[5-(5-cloro-1H-pirrolo[2,3-b]piridina-3-ilmetil)-piridina-2-il]-(6-trifluorometil-piridina-3-ilmetil)-cloridrato de amina	Tratamento do tumor tenosinovial de células gigantes, localizado e difuso.
Romanian	Clorhidrat de [5-(5-cloro-1H-pirollo[2,3-b]piridin-3-ilmetil)-piridin-2-il]-(6-trifluorometil-piridin-3-ilmetil)-amină	Tratamentul tumorilor tenosinoviale cu celule gigant, localizate și difuze
Slovak	[5-(5-chlór-1H-pyrollo[2,3-b]pyridín-3-ylmetyl)-pyridín-2-yl]-(6-trifluórmetyl-pyridín-3-ylmetyl)-amín hydrochlorid	Liečba tendosynoviálneho obrovskobunkového nádora, lokalizovaného a difúzneho typu
Slovenian	[5-(5-kloro-1H-pirollo[2,3-b]piridin-3-ilmetil)-piridin-2-yl]-(6-trifluorometil-piridin-3-ilmetil)-amin hidroklorid	Zdravljenje tenosinuvialnega gigantocelularnega lokaliziranega ali difuznega tumorja
Spanish	Clorhidrato de [5-(5-cloro-1H-pirrolo[2,3-b]piridín-3-ilmetil)-piridín-2-il]-(6-trifluorometil-piridín-3-ilmetil)-amina	Tratamiento de tumores tenosinoviales de células gigantes, formas difusa y localizada
Swedish	[5-(5-kloro-1H-pyrrolo[2,3-b]pyridin-3-ylmetyl)-pyridin-2-yl]-(6-trifluorometyl-pyridin-3-ylmetyl)-aminhydroklorid	Behandling av tenosynovial jättecellstumör, lokal och diffuse typ
Norwegian	[5-(5-kloro-1H-pyrrolo[2,3-b]pyridin-3-ylmetyl)-pyridin-2-yl]-(6-trifluorometyl-pyridin-3-ylmetyl)-amin-hydroklorid	Behandling av tenosynovial kjempecelletumor, lokalisert og diffus type

Language	Active ingredient	Indication
Icelandic	[5-(5-klór-1H-pýrróló[2,3-b]pýridín-3-ýlmetýl)-pýridín-2-ýl]-(6-þríflúormetýl-pýridín-3-ýlmetýl)-amínhýdróklóríð	Meðferð við litaðri totu-hnökrahálahimnubólgu

Withdrawn